All In Biotech

BLA 761068 · Kyowa Kirin

Crysvita

Burosumab-Twza · Injection

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Apr 17, 2018

Approved uses

5

Original approval plus efficacy supplements

Registered trials

26

8 Phase 3, 2 recruiting

FAERS reports

6,487

1,394 serious, 43 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2026.

CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 X-linked Hypophosphatemia CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. 1.2 Tumor-induced Osteomalacia CRYSVITA is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Mechanism: X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 23, 2026 Supplement 11 · Efficacy OrphanLabelLetter
  • Jun 18, 2020 Supplement 5 · Efficacy · priority review OrphanLetterLabel
  • Sep 27, 2019 Supplement 3 · Efficacy OrphanLetterLabel
  • Sep 27, 2019 Supplement 4 · Efficacy · priority review OrphanLetterLabel
  • Apr 17, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • CRYSVITA · BUROSUMAB-TWZA 10MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Burosumab" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • inappropriate schedule of product administration719
  • product dose omission issue677
  • blood phosphorus decreased584
  • pain408
  • arthralgia385
  • pain in extremity364
  • restless legs syndrome284
  • headache282
  • fatigue260
  • incorrect dose administered258
  • injection site pain246
  • bone pain216

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2018117
2019801
20201,134
20211,266
20221,336
2023417
2024454
2025493
2026469

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Crysvita (Burosumab-Twza)

2024 spending

$55.9M

Beneficiaries

179

2,127 claims

Per beneficiary

$312,265

$11,196.26 per unit

View as table
YearSpending
2020$18,706,131
2021$24,890,865
2022$31,146,027
2023$38,599,104
2024$55,895,510

Part B: Crysvita (Burosumab-Twza) · HCPCS J0584

2024 spending

$24.2M

Beneficiaries

81

801 claims

Per beneficiary

$298,435

2024 ASP limit $456.42 per unit

View as table
YearSpending
2020$11,867,168
2021$14,295,749
2022$20,535,356
2023$22,460,838
2024$24,173,202

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 37 on PubMed

Sponsor: Kyowa Kirin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.